Neutropenia due to chemotherapy for tumors
Conditions
Interventions
Observation group:None
Sponsors
Sun Yat-sen University Cancer Center (Sun Yat-sen University Affiliated Cancer Hospital, Sun Yat-sen University Cancer Institute)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with > age=18 years old; 2. Confirmed diagnosis of solid tumor by pathological histology or cytology; 3. Patients with solid tumors receiving 3-week regimen chemotherapy or 4-week regimen chemotherapy; 4. Patients who need to undergo primary prevention (use of G-CSF 24~72h after the first use of chemotherapy drugs with myelosuppression to prevent the occurrence of febrile neutropenia (FN)) or secondary prevention (if the patient developed FN or dose-limiting neutropenia in the previous chemotherapy cycle, the next chemotherapy cycle can be considered for prophylactic use of G-CSF); (Febrile neutropenia (FN): oral temperature > 38.3°C (axillary temperature >38.1°C) or oral temperature > 38.0°C (axillary temperature > 37.8°C) measured twice in 2 hours with an ANC =3.5×10 9/L, ANC>=1.5×10 9/L.
Exclusion criteria
Exclusion criteria: 1. Have received any antibody-drug conjugate (ADC) drugs and other drugs with potential blood toxicity; 2. Patients receiving intermittent or continuous chemotherapy regimens such as nab-paclitaxel and capecitabine; 3. Received extensive radiotherapy (>25% of total bone marrow); 4. Patients with obvious dysfunction of important organs such as heart, lung, liver, kidney, etc.: liver function index (ALT, TBil) > 2.5ULN, liver function index (ALT, TBil) >5ULN in patients with tumor metastasis, hepatitis B virus infection, hepatitis C virus infection or liver cirrhosis; Renal function Cr>1.5ULN; 5. Pregnant or lactating female patients; 6. Patients who have a clear refusal of clinical examination data for medical research in the patient's medical record.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade 3 and above neutropenia during chemotherapy cycles.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of febrile neutropenia (FN) during chemotherapy cycles;Antibiotic use and incidence of infection;;Incidence of chemotherapy drug taper due to neutropenia;;Incidence of chemotherapy delay due to FN or infection;;The rate and length of hospitalization associated with CIN;; | — |
Countries
China
Contacts
Public ContactShi Yanxia
Sun Yat-sen University Cancer Center
Outcome results
None listed